Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017

Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017

After a horrible 2016 following the loss of its lead drug candidate, Alnylam Pharmaceuticals (NASDAQ: ALNY) has had a pretty stellar year, up 238% so far.

Much of that increase has come in the last few months after Alnylam and its partner, Sanofi (NYSE: SNY), announced that Alnylam's new lead drug, patisiran, which treats hereditary ATTR amyloidosis (hATTR), passed the phase 3 Apollo trial. A few months later, the companies presented details of the trial at a medical meeting, demonstrating how much the drug helped patients compared to placebo.

Continue reading

Source: Fool.com